Okuda State-of-the-Art Lecture


The Scientific Program Committee for Asia Pacific Digestive Week (APDW) nominates three (3) potential lecturers and appropriate topics.

  • Potential nominees should come from more than one country within the region
  • The list of nominees should be forwarded to the JGH Foundation by 31 August in the year preceding the meeting
  • The list should be in order of preference
  • The Trustees of the JGH Foundation will make the final decision on the selection of the Okuda Lecturer
  • The decision on the selected nominee will be conveyed to the APDW organisers
  • The organisers will be responsible for notifying the selected nominee and making all arrangements.


The funding package is to assist in covering the following expenses:

  • Return airfares economy for national sector and business class for international sector (or two economy class airfares for the full trip to equivalent cost) between home city and venue for regional meeting (APDW)
  • Accommodation for the duration of APDW
  • Honorarium of US$2,000 for submission of manuscript at the time of the meeting for publication in the Journal of Gastroenterology and Hepatology (JGH).

APDW organisers must ensure that receipts and the manuscript are received prior to reimbursement of funds. The JGH Foundation will reimburse the APDW organisers on presentation of an invoice with the relevant receipts attached.


The Okuda State of the Art Lecturer is required to submit a manuscript at the time of the meeting that will cover the content of his/her lectureship. The manuscript should be structured as a review article between 3,000-5,000 words and between 3-8 tables and figures. It is expected that this will be a detailed and learned exposé of the topic concerned, and will also emphasise practical points for clinicians and investigators. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide

Past Award Recipients

Year Recipient City Topic
2017 Ching Lung Lai Hong Kong Chronic Hepatitis B: HBsAg seroclearance, cccDNA and Treatment under Trial
2016 John Windsor Auckland Novel strategies for treating severe acute pancreatitis
2015 Edward Gane Auckland Advances in HCV Therapy- Towards a Global HCV Elimination
2014 Stephen Locarnini Melbourne New Therapeutic Targets Against Hepatitis B Virus: The Need for Molecular and Immune Based Treatments
2013 Fu-sheng Wang Beijing Immune disorders lead to liver damage and influence antiviral efficacy in patients with chronic HBV infection
2012 Jia-Horng Kao Taipei Risk stratification for HBV-related HCC, Jia Horng Kao, Taipei
2011 Mashashi Mizokami Chiba Optimising Treatment for Chronic Hepatitis C - incorporating molecular medicine into clinical practice
2010 Anna Suk-Fong Lok Michigan Does antiviral therapy for hep B & C prevent HCC?
2009 Ding-Shinn Chen Taipei Towards Elimination and Eradication of Hepatitis B
2008 Masashi Mizokami Nagoya Management of hepatocellular carcinoma; From surveillance to molecular targeted therapy.
2007 No award made
2006 Malcolm Alison London Stem Cell Therapy in Liver Diseases
2005 Sung-Gyu Lee Seoul Asian Contribution to living donor liver transplantation
2004 Daiming Fan Xian A bird’s-eye view on gastric cancer research of the past 25 years
2003 Shiu-Kum Lam Hong Kong The role of cyclo-oxygenase (COX) in GI Diseases
2002 Yun-Fan Liaw Taipei Hepatitis flares and HBeAg seroconversion: Implications in anti-HBV